Pharmaceutical intermediates
Larotrectinib Intermediates
1 pharmaceutical intermediate for Larotrectinib. Indication: Solid tumours.
About Larotrectinib
- Originator
- Bayer Healthcare Pharmaceuticals Inc
- Indication
- Solid tumours
- Approved Date
- 11/26/2018
- DS/DP
- 11/21/2029
Available intermediates
1 intermediate currently listed for Larotrectinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (R)-2-(2,5-Difluorophenyl)pyrrolidine D-malate | 1919868-77-1 | / | / |
Building toward Larotrectinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →